Prot #CA180399: An Open Label, Randomized (2:1) Phase 2b Study of Dasatinib vs. Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy with 400 mg Imatinib

  • Frankfurt, Olga (PD/PI)

Project: Research project

Project Details

Effective start/end date4/8/134/8/19


  • ICON Clinical Research, LLC (Prot #CA180399 // Prot #CA180399)
  • Bristol-Myers Squibb Company (Prot #CA180399 // Prot #CA180399)